Home » The Fate of The Russell Depends on the Biotech Sector – That’s Not Good

The Fate of The Russell Depends on the Biotech Sector - That's Not Good
It is going to be an exciting day for the stock market with the Russell fate dependant on the biotech sector, could it get any worse?

The Fate of The Russell Depends on the Biotech Sector – That’s Not Good

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary and join the 1,905 subscribers getting it for FREE every day!

Follow Us on StockTwits

August 28 – Stock mentions: SPY, IWM, XBI, BAC, C, USB, JPM, WFC

US Markets

  • S&P 500 Futures +3.25 points
  • 10-Year Yield 1.47%
  • Dollar Index 98.09
  • Oil $55.77
  • VIX 20.5

International Markets

  • KOSPI +0.86%
  • Shanghai -0.29%
  • HSI -0.19%
  • Nikkei +0.11%
  • FTSE +0.25%
  • DAX -0.76%

Premium content:

S&P 500 (SPY)

S&P 500 is pointing to a flat opening, with 2876 act as strong resistance for the S&P 500 futures. Again not much has changed with upside resistance 2900 and downside support around 2825.

spx, sp500

Russell (IWM)

The Russell should be the primary focus today, as a break down would be a negative sign for the S&P 500 as well. We will want to see Russell stay in a region above 1450 to 1455.

russell

And after looking through the top weightings among the Russell 2000, it became rather clear to me that perhaps the biotech sector may be the key to where the Russell 2000 goes. One can see in the next chart how closely correlated the two are. I’m not sure that we want to have to depend on the biotech sector these days, as the group’s performance has been rather horrible.  Plus it will take just a single thought by anyone in politics to have about drug pricing to get the sector falling.

biotech, russell

Dumping the banks

The financials are going to continue to struggle too, as the yield curve inversion continues to steepen. I continue to believe that the cycle is around the lows, and is likely to start reversing higher.

For now, the banks are the group to avoid. I don’t want a thing about buybacks, the group has gone nowhere despite the buybacks, they have meant nothing so far.

Citigroup (C)

Citigroup is one such stock that has approached a break down towards a gap fill at around $58.50.

citigroup, c

JPMorgan (JPM)

JPMorgan is nearing a breakdown that could send it to $101.90.

jpmorgan

Bank of America (BAC)

Bank of America to $25.75

bank of america

Wells Fargo (WFC)

Wells Fargo to $43.25

wells fargo

US Banc (USB)

And US Banc to $49.50

usbancorp

That was easy.

-Mike

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.